脊柱关节炎相关IgA肾病的肾脏结局
这项回顾性研究纳入32例经活检确诊IgA肾病且明确诊断脊柱关节炎的患者,中位随访5.9年。结果显示尽管多数使用RAS抑制剂且13/32合用激素,肾脏结局仍较差:41%患者eGFR下降>50%,12.5%进展至终末期肾病。高血压、蛋白尿水平及牛津分类S和T评分与CKD IV-V期风险相关。
要点
- 脊柱关节炎相关IgA肾病肾脏结局差,41%患者eGFR下降>50%
- 高血压、蛋白尿及牛津S/T评分与进展至CKD IV-V期相关
- TNF-α阻断似未影响eGFR下降速率
核心结论
- 脊柱关节炎相关IgA肾病与不良肾脏结局相关,尽管频繁使用激素。
- TNF-α阻断在该背景下似乎不影响eGFR下降速率。
研究设计与样本
- 回顾性研究纳入32例经活检确诊IgA肾病且明确诊断脊柱关节炎的患者,男女比9:1,诊断脊柱关节炎和IgA肾病的中位年龄分别为27岁和37岁。
- 肾脏活检集中阅片并按IgA肾病牛津分类评分。
主要发现
- HLA-B27阳性率90%,60%患者表现为强直性脊柱炎。
- 基线平均eGFR为84 ± 26 ml/min per 1.73 m2,尿蛋白肌酐比为0.19 g/mmol。
- 肾活检显示新月体占33%,间质炎症占18%。
- 中位随访5.9年后,4例(12.5%)达到终末期肾病,41%患者eGFR下降>50%,平均年eGFR下降速率为-4.3 ± 6.7 ml/min per 1.73 m2。
- 随访期间达到CKD IV或V期的风险与高血压、蛋白尿水平及基线牛津分类S和T评分相关。
临床怎么用
- 对脊柱关节炎相关IgA肾病患者应关注高血压和蛋白尿控制,并依据牛津S和T评分评估进展风险。
局限性
- 回顾性研究,样本量较小(32例),可能限制结论的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy (IgAN) can be associated with spondyloarthritis (SpA). The course of SpA-associated IgAN remains largely unknown due to the absence of large cohorts. METHODS: This retrospective study included patients with biopsy-proven IgAN and definite SpA. Kidney biopsies were centrally examined and scored according to the IgAN Oxford Classification. Thirty-two patients fulfilled the inclusion criteria, with a male:female ratio of 9:1 and median age of 27 and 37 years at SpA and IgAN diagnosis, respectively. HLA-B27 was positive in 90% of cases, and most patients (60%) presented with ankylosing spondylitis. The mean baseline estimated glomerular filtration rate (eGFR) was 84 ± 26 ml/min per 1.73 m2, and the urine protein-to-creatinine ratio was 0.19 g/mmol. RESULTS: Renal biopsy revealed frequent presence of crescents (33%) and interstitial inflammation (18%). Despite almost constant use of renin-angiotensin system inhibitors, combined with steroids in 13 of 32 patients, renal outcome was particularly poor. After a median follow-up of 5.9 years, 4 patients (12.5%) reached end-stage renal disease and 41% of patients experienced a >50% decrease of eGFR. The mean annual eGFR decline rate was -4.3 ± 6.7 ml/min per 1.73 m2. The risk of reaching class IV or V chronic kidney disease (CKD) stage during follow-up was associated with the presence of hypertension, level of proteinuria, and baseline S- and T-scores of the Oxford. CONCLUSION: SpA-associated IgAN is associated with a poor renal outcome, despite frequent use of steroids. Tumor necrosis factor (TNF)-α blockade did not appear to influence the rate of eGFR decline in this setting.
引用
- Champtiaux N, Lioté F, El Karoui K, et al. Spondyloarthritis-Associated IgA Nephropathy. Kidney Int Rep. 2020. PMID: 32518863. doi:10.1016/j.ekir.2020.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。